Vertex Pharmaceuticals Inc / Ma (VRTX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $508.75, +2.06% vs the prior close of $498.50.
- Volume 2.26M shares, 2.1x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VRTX rises 2.1% to $508.75 on 2.1x normal volume. Closed at $508.75, +2.06% vs the prior close of $498.50. Day range $507.21–$517.68, opened at $514.91.
VRTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — VRTX rises 2.1% to $508.75 on 2.1x normal volume
- Closed at $508.75, +2.06% vs the prior close of $498.50. Day range $507.21–$517.68, opened at $514.91.
- Volume was 2.26M shares, 2.1x its 50-day average of 1.10M — unusually heavy trading.
- Price is -2.6% vs its 50-day average ($522.23) and +7.0% vs its 200-day average ($475.67).
- 52-week range $403.16–$560.25; today's close sits at 67% of that range, 9.2% below the 52-week high.
Oct 14, 2026 — VRTX rises 2.7% to $498.50 on 1.9x normal volume
- Closed at $498.50, +2.74% vs the prior close of $485.22. Day range $487.54–$502.94, opened at $490.45.
- Volume was 2.09M shares, 1.9x its 50-day average of 1.10M — unusually heavy trading.
- Price is -4.5% vs its 50-day average ($521.75) and +4.9% vs its 200-day average ($475.43).
- 52-week range $403.16–$560.25; today's close sits at 61% of that range, 11.0% below the 52-week high.
Oct 13, 2026 — VRTX slides 4.3% to $485.22, a 1-month low
- Closed at $485.22, -4.30% vs the prior close of $507.00. Day range $484.08–$508.57, opened at $507.55.
- Volume was 1.19M shares, 1.1x its 50-day average of 1.10M.
- Price is -6.9% vs its 50-day average ($521.35) and +2.1% vs its 200-day average ($475.25).
- 52-week range $402.58–$560.25; today's close sits at 52% of that range, 13.4% below the 52-week high.
Oct 12, 2026 — VRTX dips 0.6% to $507.00
- Closed at $507.00, -0.60% vs the prior close of $510.08. Day range $506.00–$514.80, opened at $512.44.
- Volume was 952.70K shares, 0.9x its 50-day average of 1.10M.
- Price is -2.7% vs its 50-day average ($521.06) and +6.7% vs its 200-day average ($475.14).
- 52-week range $402.58–$560.25; today's close sits at 66% of that range, 9.5% below the 52-week high.
Oct 9, 2026 — VRTX rises 1.4% to $510.08
- Closed at $510.08, +1.36% vs the prior close of $503.25. Day range $502.06–$514.90, opened at $502.11.
- Volume was 1.48M shares, 1.3x its 50-day average of 1.10M.
- Price is -2.0% vs its 50-day average ($520.46) and +7.4% vs its 200-day average ($474.90).
- 52-week range $402.58–$560.25; today's close sits at 68% of that range, 9.0% below the 52-week high.
Oct 8, 2026 — VRTX dips 0.5% to $503.25
- Closed at $503.25, -0.47% vs the prior close of $505.64. Day range $498.90–$507.87, opened at $503.14.
- Volume was 1.49M shares, 1.4x its 50-day average of 1.10M.
- Price is -3.2% vs its 50-day average ($519.90) and +6.0% vs its 200-day average ($474.65).
- 52-week range $402.58–$560.25; today's close sits at 64% of that range, 10.2% below the 52-week high.
Oct 7, 2026 — VRTX rises 0.7% to $505.64
- Closed at $505.64, +0.66% vs the prior close of $502.31. Day range $503.94–$511.51, opened at $504.08.
- Volume was 806.60K shares, 0.7x its 50-day average of 1.11M.
- Price is -2.7% vs its 50-day average ($519.50) and +6.6% vs its 200-day average ($474.42).
- 52-week range $400.86–$560.25; today's close sits at 66% of that range, 9.7% below the 52-week high.
Oct 6, 2026 — VRTX ends flat (-0.2%) to $502.31, a 1-month low, 6 down days in a row
- Closed at $502.31, -0.24% vs the prior close of $503.50. Day range $496.33–$507.41, opened at $505.00.
- Volume was 775.00K shares, 0.7x its 50-day average of 1.13M.
- Price is -3.3% vs its 50-day average ($519.19) and +5.9% vs its 200-day average ($474.12).
- 52-week range $400.74–$560.25; today's close sits at 64% of that range, 10.3% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — VRTX ends flat (-0.2%) to $503.50, a 1-month low, 5 down days in a row
- Closed at $503.50, -0.24% vs the prior close of $504.73. Day range $496.15–$506.01, opened at $504.78.
- Volume was 914.90K shares, 0.8x its 50-day average of 1.14M.
- Price is -2.9% vs its 50-day average ($518.73) and +6.3% vs its 200-day average ($473.86).
- 52-week range $400.74–$560.25; today's close sits at 64% of that range, 10.1% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — VRTX dips 0.4% to $504.73, a 1-month low, 4 down days in a row
- Closed at $504.73, -0.40% vs the prior close of $506.74. Day range $499.95–$509.50, opened at $509.50.
- Volume was 939.60K shares, 0.8x its 50-day average of 1.15M.
- Price is -2.6% vs its 50-day average ($518.20) and +6.6% vs its 200-day average ($473.62).
- 52-week range $400.74–$560.25; today's close sits at 65% of that range, 9.9% below the 52-week high.
- That makes 4 straight losses.
VRTX latest news & SEC filings
Every SEC filing by or about VRTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 10, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · 3 — Initial insider ownership statement (Form 3)
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 1, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 31, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 27, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $3.33B (prior year $2.96B) (+12.5% vs Jun 30, 2025)
- Net income: $1.10B (prior year $1.03B) (+6.5% vs Jun 30, 2025)
- Diluted EPS: $4.31 (prior year $3.99) (+8.0% vs Jun 30, 2025)
Aug 3, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 23, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 7, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade VRTX
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: May 4, 2026, Feb 12, 2026, Nov 3, 2025. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.12% (largest 4.3%).
- Liquidity: about 1.22M shares (≈$620.33M) trade per day on average.
- 52-week position: $508.75 vs a range of $403.16–$560.25 (67% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Duncan Mckechnie sold 1,541 shares on Jul 2, 2026.
- Latest filings: 8-K Sep 1, 2026; 10-Q Aug 4, 2026; 8-K Aug 3, 2026.
- Share count: 253.46M shares outstanding (Jul 31, 2026), -1.1% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VRTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 514.91 | 517.68 | 507.21 | 508.75 | 2.26M |
| Oct 14, 2026 | 490.45 | 502.94 | 487.54 | 498.50 | 2.09M |
| Oct 13, 2026 | 507.55 | 508.57 | 484.08 | 485.22 | 1.19M |
| Oct 12, 2026 | 512.44 | 514.80 | 506.00 | 507.00 | 952.70K |
| Oct 9, 2026 | 502.11 | 514.90 | 502.06 | 510.08 | 1.48M |
| Oct 8, 2026 | 503.14 | 507.87 | 498.90 | 503.25 | 1.49M |
| Oct 7, 2026 | 504.08 | 511.51 | 503.94 | 505.64 | 806.60K |
| Oct 6, 2026 | 505.00 | 507.41 | 496.33 | 502.31 | 775.00K |
| Oct 5, 2026 | 504.78 | 506.01 | 496.15 | 503.50 | 914.90K |
| Oct 2, 2026 | 509.50 | 509.50 | 499.95 | 504.73 | 939.60K |
| Oct 1, 2026 | 522.39 | 523.52 | 505.27 | 506.74 | 1.19M |
| Sep 30, 2026 | 525.26 | 529.72 | 522.74 | 522.81 | 1.15M |
| Sep 29, 2026 | 522.22 | 529.46 | 519.25 | 526.73 | 688.80K |
| Sep 28, 2026 | 524.27 | 529.89 | 521.16 | 527.67 | 823.50K |
| Sep 25, 2026 | 522.55 | 527.69 | 518.92 | 526.19 | 756.20K |
| Sep 24, 2026 | 515.56 | 528.99 | 515.30 | 522.38 | 940.90K |
| Sep 23, 2026 | 515.60 | 525.43 | 509.56 | 516.34 | 1.21M |
| Sep 22, 2026 | 521.69 | 525.97 | 508.14 | 514.99 | 1.39M |
| Sep 21, 2026 | 506.85 | 514.10 | 501.01 | 510.72 | 906.50K |
| Sep 18, 2026 | 516.34 | 518.10 | 505.01 | 508.34 | 2.43M |
About Vertex Pharmaceuticals Inc / Ma
Vertex Pharmaceuticals Inc / Ma (VRTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: MA. Fiscal year ends December 31. SEC CIK 875320.
VRTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sangeeta N. Bhatia | Director | May 5, 2026 |
| Lloyd Carney | Director | May 5, 2026 |
| Alan M Garber | Director | Jul 17, 2026 |
| Reshma Kewalramani | CEO & President | Mar 3, 2026 |
| Jeffrey M Leiden | Executive Chairman | Feb 26, 2026 |
| Michel Lagarde | Director | May 5, 2026 |
| Diana Mckenzie | Director | May 5, 2026 |
| Bruce I Sachs | Director | Aug 31, 2026 |
| Jennifer Schneider | Director | May 5, 2026 |
| Nancy Thornberry | Director | May 5, 2026 |
| Suketu Upadhyay | Director | May 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David Altshuler | EVP, Chief Scientific Officer | Jan 26, 2026 |
| Kristen Ambrose | SVP & Chief Accounting Officer | Sep 1, 2026 |
| Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | Feb 26, 2026 |
| Jonathan Biller | EVP and Chief Legal Officer | Feb 26, 2026 |
| Carmen Bozic | EVP and CMO | Jun 30, 2026 |
| Mark E. Bunnage | EVP, Chief Scientific Officer | May 19, 2026 |
| Reshma Kewalramani | CEO & President | Mar 3, 2026 |
| Jeffrey M Leiden | Executive Chairman | Feb 26, 2026 |
| Joy Liu | EVP and Chief Legal Officer | Jul 6, 2026 |
| Duncan Mckechnie | EVP, Chief Commercial Officer | Jul 7, 2026 |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | Jul 23, 2026 |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Jul 23, 2026 |
| Charles F Jr Wagner | EVP, CO & FO | Feb 26, 2026 |
| Grunsven Jasper Van | EVP, CP and NPPO | Sep 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Duncan Mckechnie | Sale | 1,541 | $519.00 |
| Jul 2, 2026 | Ourania Tatsis | Sale | 1,500 | $524.99 |
| Jul 1, 2026 | Joy Liu | Sale | 828 | $502.71 |
| Jun 26, 2026 | Carmen Bozic | Sale | 596 | $482.50 |
| Jun 18, 2026 | Carmen Bozic | Sale | 1,020 | $462.17 |
| Jun 15, 2026 | Carmen Bozic | Sale | 4,062 | $450.00 |
| Jun 5, 2026 | Carmen Bozic | Sale | 1,745 | $450.00 |
| Jun 1, 2026 | Joy Liu | Sale | 828 | $439.91 |
| May 29, 2026 | Carmen Bozic | Sale | 1,974 | $450.00 |
| May 15, 2026 | Mark E. Bunnage | Sale | 33 | $453.45 |
| May 15, 2026 | Carmen Bozic | Sale | 1,354 | $453.45 |
| May 12, 2026 | Carmen Bozic | Sale | 6,988 | $450.00 |
| May 4, 2026 | Sangeeta N. Bhatia | Sale | 318 | $423.73 |
| May 1, 2026 | Joy Liu | Sale | 1,104 | $425.02 |
| Apr 1, 2026 | Joy Liu | Sale | 978 | $449.17 |
VRTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $12.00B | $3.95B | 15.32 | $3.63B |
| Dec 31, 2024 | $11.02B | $-535.60M | -2.08 | $-492.60M |
| Dec 31, 2023 | $9.87B | $3.62B | 13.89 | $3.54B |
| Dec 31, 2022 | $8.93B | $3.32B | 12.82 | $4.13B |
| Dec 31, 2021 | $7.57B | $2.34B | 9.01 | $2.64B |
Latest balance sheet: total assets $27.42B, total liabilities $7.18B, cash $6.14B (as of Jun 30, 2026).
VRTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $470.72 |
| May 4, 2026 | 8-K Item 2.02 (results) | $429.85 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $465.02 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $426.00 |
| Aug 4, 2025 | 8-K Item 2.02 (results) | $472.27 |
| May 5, 2025 | 8-K Item 2.02 (results) | $500.19 |
| Feb 10, 2025 | 8-K Item 2.02 (results) | $469.97 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $472.80 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Feb 5, 2024 | 8-K Item 2.02 (results) | — |
| Nov 6, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on VRTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.